小肾肿物的管理:美国临床肿瘤学会临床实践指南
该指南针对小肾肿物(SRM)患者的管理选项提供推荐,证据来自2000至2015年发表的83项研究(含20项系统综述和63项原始研究),结局包括无复发生存、疾病特异性生存和总生存。推荐涉及活检、主动监测、部分肾切除术、经皮热消融和根治性肾切除术的选择,以及治疗后肾病转诊的考虑。
要点
- 所有SRM患者若活检结果可能改变管理方案,应考虑活检。
- 显著合并症且预期寿命有限的患者,主动监测应作为初始管理选项。
- SRM的标准治疗是部分肾切除术,应提供给有干预指征且肿瘤适合该术式的患者。
核心结论
- 基于肿瘤特异性发现和竞争性死亡风险,所有SRM患者若活检结果可能改变管理,应考虑活检。
研究设计与样本
- 通过文献检索和前瞻性定义的研究选择,检索2000至2015年发表的系统综述、Meta分析、随机临床试验、前瞻性比较观察研究和回顾性研究。
- 83项研究(包括20项系统综述和63项原始研究)符合纳入标准,构成指南推荐的证据基础。
主要发现
- 结局包括无复发生存、疾病特异性生存和总生存。
关键数值与推荐
- 所有SRM患者若活检结果可能改变管理,应考虑活检。
- 显著合并症和预期寿命有限的患者,主动监测应作为初始管理选项。
- SRM的部分肾切除术是标准治疗,应提供给有干预指征且肿瘤适合该术式的所有患者。
- 经皮热消融若可可靠实现完全消融,应考虑为选项。
- SRM的根治性肾切除术应仅保留给肿瘤显著复杂不适合部分肾切除的患者,或即使在专业中心行部分肾切除也可能导致不可接受并发症的患者。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose To provide recommendations for the management options for patients with small renal masses (SRMs). Methods By using a literature search and prospectively defined study selection, we sought systematic reviews, meta-analyses, randomized clinical trials, prospective comparative observational studies, and retrospective studies published from 2000 through 2015. Outcomes included recurrence-free survival, disease-specific survival, and overall survival. Results Eighty-three studies, including 20 systematic reviews and 63 primary studies, met the eligibility criteria and form the evidentiary basis for the guideline recommendations. Recommendations On the basis of tumor-specific findings and competing risks of mortality, all patients with an SRM should be considered for a biopsy when the results may alter management. Active surveillance should be an initial management option for patients who have significant comorbidities and limited life expectancy. Partial nephrectomy (PN) for SRMs is the standard treatment that should be offered to all patients for whom an intervention is indicated and who possess a tumor that is amenable to this approach. Percutaneous thermal ablation should be considered an option if complete ablation can reliably be achieved. Radical nephrectomy for SRMs should only be reserved for patients who possess a tumor of significant complexity that is not amenable to PN or for whom PN may result in unacceptable morbidity even when performed at centers with expertise. Referral to a nephrologist should be considered if chronic kidney disease (estimated glomerular filtration rate < 45 mL/min/1.73 m2) or progressive chronic kidney disease occurs after treatment, especially if associated with proteinuria.
引用
- Finelli A, Ismaila N, Bro B, et al. Management of Small Renal Masses: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017. PMID: 28095147. doi:10.1200/JCO.2016.69.9645
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。